FDA Inspection 971997 — Anna Elzakowska-Bober
The FDA completed an inspection of Anna Elzakowska-Bober on April 22, 2016 in Swidnik. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 22, 2016
- Fiscal Year
- 2016
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Swidnik (Poland)
Additional Details
Clinical Investigator (CI)